Celera Genomics

Author: Norman Peter  

Publisher: Informa Healthcare

ISSN: 1354-3776

Source: Expert Opinion on Therapeutic Patents, Vol.14, Iss.9, 2004-09, pp. : 1345-1349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

This article is the first of a series that examines the patenting policy of the leading genomics companies. Celera is a public company, although it is a subsidiary of Applera Corp., and was founded in 1998 to exploit the sequence of the human genome by licensing its genomic databases and patents. In 2001 its strategy changed with the acquisition of the biotechnology company Axys Pharmaceuticals, and Celera has evolved into a biotechnology company seeking to exploit small-molecule therapeutics and antibodies in addition to its genomic databases. Analysis of its patenting activity indicates that the rate of filing of genomic applications peaked in 2002, whilst there is little evidence of the acquisition of Axys stimulating patent filings from that group.